Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada

BACKGROUND: Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included relatively few elderly participants. We assess single-dose mRNA vaccine effectiveness (VE) in adults ≥ 70 years old in British Columbia, C...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Setayeshgar, Solmaz, Zou, Macy, Prystajecky, Natalie, Tyson, John R, Galanis, Eleni, Naus, Monika, Patrick, David M, Sbihi, Hind, El Adam, Shiraz, Henry, Bonnie, Hoang, Linda M N, Sadarangani, Manish, Jassem, Agatha N, Krajden, Mel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406884/
https://www.ncbi.nlm.nih.gov/pubmed/34244723
http://dx.doi.org/10.1093/cid/ciab616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406884/
https://www.ncbi.nlm.nih.gov/pubmed/34244723
http://dx.doi.org/10.1093/cid/ciab616

Ejemplares similares